Risk of HBV reactivation in HCC patients undergoing combination therapy of PD-1 inhibitors and angiogenesis inhibitors in the antiviral era

CONCLUSION: HBeAg-positive patients receiving combination therapy have a 17-fold higher risk of HBVr than HBeAg-negative patients with PD-1 inhibitors monotherapy.PMID:38530426 | DOI:10.1007/s00432-024-05677-7

Source: Cell Research - March 26, 2024 Category: Cytology Authors: Rui Wang Guili Tan Dingjia Lei Yadi Li JiaoJiao Gong Yao Tang Hao Pang Huating Luo Bo Qin Source Type: research